Inogen (INGN) Projected to Post Quarterly Earnings on Tuesday

Inogen (NASDAQ:INGN) is projected to release its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Inogen to post earnings of ($0.36) per share and revenue of $82.00 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Inogen Trading Down 0.7%

Shares of INGN opened at $5.79 on Friday. Inogen has a twelve month low of $5.48 and a twelve month high of $11.94. The firm has a market capitalization of $157.20 million, a P/E ratio of -5.73 and a beta of 1.79. The stock’s fifty day simple moving average is $6.31 and its 200 day simple moving average is $7.26.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Inogen in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $11.00.

Institutional Investors Weigh In On Inogen

A number of large investors have recently modified their holdings of INGN. Alliancebernstein L.P. raised its holdings in shares of Inogen by 3.9% during the 3rd quarter. Alliancebernstein L.P. now owns 51,120 shares of the medical technology company’s stock valued at $418,000 after buying an additional 1,900 shares during the period. Russell Investments Group Ltd. grew its position in Inogen by 14.6% in the fourth quarter. Russell Investments Group Ltd. now owns 19,543 shares of the medical technology company’s stock valued at $131,000 after acquiring an additional 2,487 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Inogen by 7.0% during the second quarter. Rhumbline Advisers now owns 39,059 shares of the medical technology company’s stock valued at $275,000 after purchasing an additional 2,561 shares during the period. American Century Companies Inc. raised its stake in shares of Inogen by 4.9% during the second quarter. American Century Companies Inc. now owns 61,238 shares of the medical technology company’s stock valued at $431,000 after purchasing an additional 2,858 shares during the period. Finally, Barclays PLC boosted its stake in shares of Inogen by 4.5% in the fourth quarter. Barclays PLC now owns 81,980 shares of the medical technology company’s stock valued at $551,000 after purchasing an additional 3,515 shares during the period. Institutional investors and hedge funds own 89.94% of the company’s stock.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.